trial

Safety, Pharmacokinetics and Efficacy Study of MP-214 in Patients With Schizophrenia

NCTId NCT00862992
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 34 (actual)
Sponsored by Tanabe Pharma Corporation
Primary completion 2009-09
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
34 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2008-04
Primary completion
2009-09
Eligibility
ALL · 20 Years · 65 Years

Interventions & indications

Drugs
Cariprazine (Vraylar)

Sponsors

Tanabe Pharma CorporationLead Sponsor

Investigators

1
Teruhiko Higuchi, PresidentStudy Chair

Sites

1 total
Kure, Japan

Linked catalysts

1
Safety, Pharmacokinetics and Efficacy Study of MP-214 in Patients With Schizophr — primary completion2009-09

Facts & assertions

4 sourced
Enrollment
34
Phase
PHASE2
Primary Completion Date
2009-09
Status
COMPLETED
relationships
The graph out of here
drug
Cariprazine (Vraylar)
drug
lead_sponsor
Tanabe Pharma Corporation
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Teruhiko Higuchi, President
person